In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Could A Type 1 Diabetes Immunotherapy Be In Reach?

Executive Summary

Promising data from the likes of Provention Bio and Diamyd Medical suggest that treatment for the autoimmune disorder type 1 diabetes could soon move beyond insulin.

You may also be interested in...



EMA Accepts First Diabetes Drug Onto PRIME

Provention Bio’s teplizumab, a potentially game-changing treatment for preventing or delaying type 1 diabetes, is one of three investigational products to be newly accepted onto the European Medicines Agency’s popular priority medicines scheme.

GSK & Tolerx suffer Phase III otelixizumab setback

Targeting CD3 to treat type 1 diabetes has once again been called into question as GSK and Tolerx revealed that the Phase III DEFEND-1 study of otelixzimuab did not meet its primary endpoint in patients with new-onset autoimmune type 1 diabetes. The partners have suspended new recruitment and dosing in the DEFEND-2 study pending review of the DEFEND-1 results. Last autumn, MacroGenics and partner Eli Lilly announced that their anti-CD3 mAb failed to show efficacy in a pivotal Phase II/III trial in type 1 diabetes patients missing the same primary endpoint.

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV124388

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel